Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.

Claire F FriedmanAlexandra Snyder CharenQin ZhouMichael A CarducciAlexandre Buckley De MeritensBradley R CorrSiqing FuTravis J HollmannAlexia IasonosJason A KonnerPanagiotis A KonstantinopoulosSusan C ModesittElad SharonCarol AghajanianDmitriy Zamarin

Published in: Journal for immunotherapy of cancer (2021)

The combination of bevacizumab and atezolizumab did not meet the predefined efficacy endpoint, as addition of bevacizumab to PD-L1 blockade did not appear to enhance the ORR in cervical cancer.

Keyphrases

phase ii study
metastatic colorectal cancer
open label
locally advanced
squamous cell carcinoma
clinical trial
radiation therapy
rectal cancer
placebo controlled
double blind